Logo
Nazad
C. Ay, Katarina D Kovacevic, D. Kraemmer, C. Schoergenhofer, Georg Gelbenegger, Christa Firbas, P. Quehenberger, P. Jilma-Stohlawetz, J. Gilbert, Shuhao Zhu, M. Béliveau, Franz Koenig, A. Iorio, B. Jilma, U. Derhaschnig, I. Pabinger
9 15. 9. 2022.

The von Willebrand factor–binding aptamer rondaptivon pegol as a treatment for severe and nonsevere hemophilia A

Key Points • Rondaptivon pegol is a first-in-class prohemostatic molecule that prolongs the half-life of both endogenous FVIII and substituted FVIII.• Rondaptivon pegol could be used to enable once-weekly substitution therapy in severe hemophilia A or as prophylaxis in nonsevere hemophilia A.


Pretplatite se na novosti o BH Akademskom Imeniku

Ova stranica koristi kolačiće da bi vam pružila najbolje iskustvo

Saznaj više